wegovy

Semaglutide

The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.

Semaglutide is a modified GLP-1 analogue with a ~1-week half-life, proven to reduce body weight by 10-17%, cut cardiovascular events by 20%, resolve fatty liver disease, and slow kidney decline. Its reach now extends into addiction, sleep apnea, and neuroinflammation.